Novel paclitaxel formulations for oral application: A phase I pharmacokinetic study in patients with solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 5, 2007, Pages 635-642

  Veltkamp, S A ^a   Rosing, H ^b   Huitema, A D R ^b   Fetell, M R ^d   Nol, A ^a   Beijnen, J H ^a,b,c   Schellens, J H M ^a,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d IVAX Research Inc   (United States)

Author keywords

Cremophor free; Oral administration; Paclitaxel; Pharmacokinetics; Phase I

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; ANTIEMETIC AGENT; ASCORBYL PALMITATE; CYCLOSPORIN A; GRANISETRON; LABRASOL; MACROGOL 400; PACLITAXEL; PROPYLENE GLYCOL; SORBITAN OLEATE; TOCOFERSOLAN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIDRUG RESISTANCE 1 GENE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRINKING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASMS; PACLITAXEL;

EID: 34547838610     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0405-4     Document Type: Article

References (33)

1. Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens JHM, Beijnen JH, van Tellingen O (2002) Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 49:119-125
2. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495-503
3. Bosch TM, Meijerman I, Beijnen JH, Schellens JHM (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253-285
4. Boudreaux JP, Hayes DH, Mizrahi S, Maggiore P, Blazek J, Dick D (1993) Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant. Transplant Proc 25:1875
5. Britten CD, Baker SD, Denis LJ, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, Rowinsky EK (2000) Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res 6:3459-3468
6. Chang RK, Shojaei AH (2004) Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration. J Pharm Pharm Sci 7:8-12
7. Chang T, Benet LZ, Hebert MF (1996) The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297-303
8. de Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH (2005) Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol 59:325-334
9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
10. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199
11. Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-530
12. Kruijtzer CM, Beijnen JH, Schellens JHM (2002) Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7:516-530
13. Malingré MM, Schellens JHM, van Tellingen O, Rosing H, Koopman FJ, Duchin K, ten Bokkel Huinink WW, Swart M, Beijnen JH (2000) Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anticancer Drugs 11:813-820
14. Malingré MM, Meerum Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM (2000) Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18:2468-2475
15. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM (2001) A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 47:347-354
16. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM (2001) The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 12:351-358
17. Malingré MM, Beijnen JH, Schellens JHM (2001) Oral delivery of taxanes. Invest New Drugs 19:155-162
18. Malingré MM, Rosing H, Koopman FJ, Schellens JHM, Beijnen JH (2001) Performance of the analytical assays of paclitaxel, docetaxel, and cyclosporin in a routine hospital laboratory setting. J Liq Chromatogr Relat Technol 24:2697-2717
19. Malingré MM, Schellens JHM, van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, ten Bokkel Huinink WW, Beijnen JH (2001) The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 85:1472-1477
20. Malingré MM, ten Bokkel Huinink WW, Duchin K, Schellens JHM, Beijnen JH (2001) Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. Anticancer Drugs 12:591-593
21. Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JHM (1999) Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384
22. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112-2115
23. Sparreboom A, van Asperen J, Mayer U, et al (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035
24. Sparreboom A, van Zuylen L, Brouwer E, et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457
25. Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JHM, Beijnen JH (2006) A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomed Chromatogr 20:139-148
26. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH (1998) Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4:2293-2297
27. van Tellingen O, Huizing MT, Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH (1998) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330-335
28. van Zuylen L, Karlsson MO, Verweij J, et al (2001) Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47:309-318
29. van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125-141
30. Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema ADR, Nuijen B, Nol A, Neijnen JH, Schellens JHM (2006) A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95:729-734
31. Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JHM (2007) A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Cancer Chemother Pharmacol 59:43-50
32. Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Millward MJ (1997) Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 39:557-560
33. Wolff AC, Donehower RC, Carducci MK Cardussi MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD (2003) Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589-3597